{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:34:52Z","timestamp":1777469692193,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.xphs.2016.07.029","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:16:31Z","timestamp":1473984991000},"page":"3399-3408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis"],"prefix":"10.1016","volume":"105","author":[{"given":"Sara I.","family":"Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashwa","family":"El-Gendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry E.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory","family":"Berkland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark M.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9370","key":"10.1016\/j.xphs.2016.07.029_bib1","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(03)13374-0","article-title":"Melioidosis","volume":"361","author":"White","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.xphs.2016.07.029_bib2","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3201\/eid0912.020750","article-title":"Intensity of rainfall and severity of melioidosis, Australia","volume":"9","author":"Currie","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2016.07.029_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/0976-9668.107256","article-title":"Bioterrorism: health sector alertness","volume":"4","author":"Pinto","year":"2013","journal-title":"J\u00a0Nat Sci Biol Med"},{"issue":"4","key":"10.1016\/j.xphs.2016.07.029_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1476-5381.2010.00939.x","article-title":"Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents","volume":"161","author":"Ramasamy","year":"2010","journal-title":"Br J Pharm"},{"issue":"8665","key":"10.1016\/j.xphs.2016.07.029_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(89)90768-X","article-title":"Halving of mortality of severe melioidosis by ceftazidime","volume":"2","author":"White","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.xphs.2016.07.029_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jac\/dkm527","article-title":"Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin\/clavulanic acid and co-trimoxazole","volume":"61","author":"Sivalingam","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2016.07.029_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2014.03.053","article-title":"An overview of clinical and commercial impact of drug delivery systems","volume":"190","author":"Anselmo","year":"2014","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2016.07.029_bib8","unstructured":"Cystic Fibrosis Foundation. 2015. Available at: https:\/\/www.cff.org\/. Accessed September 7, 2016."},{"issue":"22","key":"10.1016\/j.xphs.2016.07.029_bib9","doi-asserted-by":"crossref","first-page":"10897","DOI":"10.1021\/la7020098","article-title":"Biodegradable nanoparticle flocculates for dry powder aerosol formulation","volume":"23","author":"Shi","year":"2007","journal-title":"Langmuir"},{"issue":"4","key":"10.1016\/j.xphs.2016.07.029_bib10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1021\/mp1000718","article-title":"Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization","volume":"7","author":"Aillon","year":"2010","journal-title":"Mol Pharm"},{"issue":"23","key":"10.1016\/j.xphs.2016.07.029_bib11","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/la802405p","article-title":"Pure insulin nanoparticle agglomerates for pulmonary delivery","volume":"24","author":"Bailey","year":"2008","journal-title":"Langmuir"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.07.029_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijpharm.2010.03.009","article-title":"Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent","volume":"391","author":"El-Gendy","year":"2010","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2016.07.029_bib13","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s11095-009-9886-2","article-title":"Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration","volume":"26","author":"El-Gendy","year":"2009","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2016.07.029_bib14","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/jps.21630","article-title":"Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution","volume":"98","author":"El-Gendy","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2016.07.029_bib15","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1002\/jps.23176","article-title":"Development of budesonide nanocluster dry powder aerosols: formulation and stability","volume":"101","author":"El-Gendy","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2016.07.029_bib16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejps.2011.09.014","article-title":"Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols","volume":"44","author":"El-Gendy","year":"2011","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2016.07.029_bib17","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1002\/jps.23197","article-title":"Development of budesonide nanocluster dry powder aerosols: preformulation","volume":"101","author":"El-Gendy","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2016.07.029_bib18","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/jps.23168","article-title":"Development of budesonide nanocluster dry powder aerosols: processing","volume":"101","author":"El-Gendy","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"17","key":"10.1016\/j.xphs.2016.07.029_bib19","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.1021\/la8012014","article-title":"Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins","volume":"24","author":"Peek","year":"2008","journal-title":"Langmuir"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.07.029_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2008.10.016","article-title":"Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy","volume":"369","author":"Plumley","year":"2009","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2016.07.029_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11671-008-9160-2","article-title":"Comparison of in\u00a0vitro nanoparticles uptake in various cell lines and in\u00a0vivo pulmonary cellular transport in intratracheally dosed rat model","volume":"3","author":"Lai","year":"2008","journal-title":"Nanoscale Res Lett"},{"issue":"1","key":"10.1016\/j.xphs.2016.07.029_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejpb.2011.12.015","article-title":"Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches","volume":"81","author":"Salazar","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2016.07.029_bib23","series-title":"Bulk and Tapped Density","year":"2012"},{"issue":"4","key":"10.1016\/j.xphs.2016.07.029_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/pt030428","article-title":"Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug","volume":"3","author":"Sethuraman","year":"2002","journal-title":"AAPS PharmSciTech"},{"issue":"11-12","key":"10.1016\/j.xphs.2016.07.029_bib25","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2138\/am-2000-11-1220","article-title":"Surface area and porosity of primary silicate minerals","volume":"85","author":"Brantley","year":"2000","journal-title":"Am Mineral"},{"issue":"27","key":"10.1016\/j.xphs.2016.07.029_bib26","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1021\/ja071174k","article-title":"Applicability of the BET method for determining surface areas of microporous metal-organic frameworks","volume":"129","author":"Walton","year":"2007","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.xphs.2016.07.029_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/15287398509530647","article-title":"Comparative deposition of inhaled aerosol in experimental animals and humans: a review","volume":"15","author":"Schlesinger","year":"1985","journal-title":"J\u00a0Toxicol Environ Health"},{"issue":"2","key":"10.1016\/j.xphs.2016.07.029_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","article-title":"Nanosizing: a formulation approach for poorly-water-soluble compounds","volume":"18","author":"Merisko-Liversidge","year":"2003","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.07.029_bib29","series-title":"AFHS Drug Information","first-page":"106","article-title":"Ceftazidime","year":"2015"},{"issue":"1","key":"10.1016\/j.xphs.2016.07.029_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/dkg011","article-title":"A\u00a0comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model","volume":"51","author":"Ulett","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2016.07.029_bib31","series-title":"Exploring QSAR: Hydrophobic, electronic, and steric constants","year":"1995"},{"key":"10.1016\/j.xphs.2016.07.029_bib32","series-title":"Nanocluster Compositions and Methods","year":"2011"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916416291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916416291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T10:41:25Z","timestamp":1531478485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916416291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0022354916416291"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.07.029","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}